Top Biotech Stocks
Discover companies at the forefront of medical breakthroughs and healthcare innovation. This collection of biotech stocks has been carefully selected by our professional analysts for their growth potential and contributions to revolutionary treatments.
Top Picks from This Group
Here are a few of the assets in this group. Create an account to unlock the full list.
Unlock all stocks by downloading the app for FREE
It only takes 60 seconds.
About This Group of Stocks
Our Expert Thinking
These biotech companies are pioneering revolutionary treatments using advanced technologies like CRISPR gene editing. With favorable regulatory environments expediting approvals and growing global demand for innovative healthcare solutions, this sector offers both meaningful impact and promising financial growth opportunities.
What You Need to Know
Biotech investments can offer substantial returns but typically involve longer development cycles. The industry is projected to grow from $1.55 trillion in 2023 to approximately $3.88 trillion by 2030, with regulatory support accelerating the approval of promising treatments.
Why These Stocks
We've selected established biotech leaders and innovative disruptors working on groundbreaking medical advancements. These companies are well-positioned to respond to increasing healthcare demands as global populations age, making them potentially valuable additions to a forward-looking investment portfolio.
12 Month Growth Potential
Use the growth calculator to see how much investing in these assets could return over one year.
If you invested across these assets:
in 12 months it could be worth:
+72.88%
Group Performance Snapshot
Average 12 Month Profit
On average, analysts expect assets in this group to grow 72.88% over the next year.
Stocks Rated Buy by Analysts
3 of 8 assets in this group are rated Buy by professional analysts.
Group Growth
This group averaged a 0.7% return last month.
Why You'll Want to Watch These Stocks
Medical Game-Changers
These companies are developing treatments that could transform healthcare as we know it. From gene editing to novel therapies, they're tackling our biggest health challenges.
Explosive Growth Potential
The biotech industry is projected to grow at nearly 14% annually through 2030. Getting in now means positioning yourself at the start of what could be a remarkable expansion.
More Than Just Profits
By investing in biotech, you're not just seeking returns but also supporting companies developing treatments that could save millions of lives and improve countless others.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Beyond The App Store: Europe's New Rules
Following regulatory pressure from the European Union, Google has revised its Play Store rules to permit alternative payment systems. This change creates a new investment opportunity in companies poised to benefit from a more open mobile app ecosystem.
The New Cost of Compliance: Investing in HR Tech
Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.
GLP-1s Target Liver Disease
The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.
Frequently Asked Questions
Everything you need to know about the product and billing.